TY - JOUR
T1 - 177Lu-DO3A-HSA-Z EGFR:1907
T2 - Characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas
AU - Hoppmann, Susan
AU - Qi, Shibo
AU - Miao, Zheng
AU - Liu, Hongguang
AU - Jiang, Han
AU - Cutler, Cathy S.
AU - Bao, Ande
AU - Cheng, Zhen
N1 - Funding Information:
Acknowledgments This work was supported, in part, by National Cancer Institute (NCI) grant 5R01 CA119053 and NCI In Vivo Cellular Molecular Imaging Center grant P50 CA114747. The production of 177Lu was supported by Department of Energy grant 84900-001-10.
Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/6
Y1 - 2012/6
N2 - Epidermal growth factor receptor 1 (EGFR) is an attractive target for radionuclide therapy of head and neck carcinomas. Affibody molecules against EGFR (Z EGFR) show excellent tumor localizations in imaging studies. However, one major drawback is that radiometal-labeled Affibody molecules display extremely high uptakes in the radiosensitive kidneys which may impact their use as radiotherapeutic agents. The purpose of this study is to further explore whether radiometal-labeled human serum albumin (HSA)-Z EFGR bioconjugates display desirable profiles for the use in radionuclide therapy of EGFR-positive head and neck carcinomas. The Z EFGR analog, Ac-Cys-Z EGFR:1907, was site-specifically conjugated with HSA. The resulting bioconjugate 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A)-HSA-Z EGFR:1907 was then radiolabeled with either 64Cu or 177Lu and subjected to in vitro cell uptake and internalization studies using the human oral squamous carcinoma cell line SAS. Positron emission tomography (PET), single photon emission computed tomography (SPECT), and biodistribution studies were conducted using SAS-tumor-bearing mice. Cell studies revealed a high (8.43 ± 0.55 % at 4 h) and specific (0.95 ± 0.09 % at 4 h) uptake of 177Lu-DO3A-HSA-Z EGFR:1907 as determined by blocking with nonradioactive Z EGFR:1907. The internalization of 177Lu-DO3A-HSA-Z EGFR:1907 was verified in vitro and found to be significantly higher than that of 177Lu-labeled Z EFGR at 2-24 h of incubation. PET and SPECT studies showed good tumor imaging contrasts. The biodistribution of 177Lu-DO3A-HSA-Z EGFR:1907 in SAS-tumor-bearing mice displayed high tumor uptake (5.1 ± 0.44 % ID/g) and liver uptake (31.5 ± 7.66 % ID/g) and moderate kidney uptake (8.5 ± 1.08 % ID/g) at 72 h after injection. 177Lu-DO3A-HSA-Z EGFR:1907 shows promising in vivo profiles and may be a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
AB - Epidermal growth factor receptor 1 (EGFR) is an attractive target for radionuclide therapy of head and neck carcinomas. Affibody molecules against EGFR (Z EGFR) show excellent tumor localizations in imaging studies. However, one major drawback is that radiometal-labeled Affibody molecules display extremely high uptakes in the radiosensitive kidneys which may impact their use as radiotherapeutic agents. The purpose of this study is to further explore whether radiometal-labeled human serum albumin (HSA)-Z EFGR bioconjugates display desirable profiles for the use in radionuclide therapy of EGFR-positive head and neck carcinomas. The Z EFGR analog, Ac-Cys-Z EGFR:1907, was site-specifically conjugated with HSA. The resulting bioconjugate 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A)-HSA-Z EGFR:1907 was then radiolabeled with either 64Cu or 177Lu and subjected to in vitro cell uptake and internalization studies using the human oral squamous carcinoma cell line SAS. Positron emission tomography (PET), single photon emission computed tomography (SPECT), and biodistribution studies were conducted using SAS-tumor-bearing mice. Cell studies revealed a high (8.43 ± 0.55 % at 4 h) and specific (0.95 ± 0.09 % at 4 h) uptake of 177Lu-DO3A-HSA-Z EGFR:1907 as determined by blocking with nonradioactive Z EGFR:1907. The internalization of 177Lu-DO3A-HSA-Z EGFR:1907 was verified in vitro and found to be significantly higher than that of 177Lu-labeled Z EFGR at 2-24 h of incubation. PET and SPECT studies showed good tumor imaging contrasts. The biodistribution of 177Lu-DO3A-HSA-Z EGFR:1907 in SAS-tumor-bearing mice displayed high tumor uptake (5.1 ± 0.44 % ID/g) and liver uptake (31.5 ± 7.66 % ID/g) and moderate kidney uptake (8.5 ± 1.08 % ID/g) at 72 h after injection. 177Lu-DO3A-HSA-Z EGFR:1907 shows promising in vivo profiles and may be a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
KW - Affibody
KW - Epidermal growth factor receptor
KW - Human serum albumin
KW - Lu
KW - Radionuclide therapy
UR - http://www.scopus.com/inward/record.url?scp=84862825103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862825103&partnerID=8YFLogxK
U2 - 10.1007/s00775-012-0890-3
DO - 10.1007/s00775-012-0890-3
M3 - Article
C2 - 22418921
AN - SCOPUS:84862825103
VL - 17
SP - 709
EP - 718
JO - Journal of Biological Inorganic Chemistry
JF - Journal of Biological Inorganic Chemistry
SN - 0949-8257
IS - 5
ER -